Previous Close | 10.91 |
Open | 10.74 |
Bid | 11.15 x 800 |
Ask | 11.25 x 1400 |
Day's Range | 10.14 - 11.31 |
52 Week Range | 8.75 - 101.39 |
Volume | |
Avg. Volume | 6,826,378 |
Market Cap | 849.079M |
Beta (5Y Monthly) | 1.88 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -7.27 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 81.33 |
Is Novavax stock a buy as the company plans to update its Covid shot, in line with FDA experts' advice? Is NVAX stock a buy right now?
Novavax (NASDAQ: NVAX) has offered investors just such a ride over the past few years. Initial gains came as investors bet on Novavax's chances of bringing a coronavirus vaccine to market; declines occurred after the vaccine entered the market later than rival products did. Now, as we start a new year, you might be wondering what to do about Novavax.
Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.